LEADER 03400nam  2200625Ia 450 
001 9910806236703321
005 20230725024937.0
010   $a1-118-09777-7
010   $a1-282-78289-4
010   $a9786612782893
010   $a0-470-89038-X
010   $a0-470-89037-1
035   $a(CKB)2670000000047173
035   $a(EBL)589068
035   $a(OCoLC)669165475
035   $a(SSID)ssj0000433695
035   $a(PQKBManifestationID)11279317
035   $a(PQKBTitleCode)TC0000433695
035   $a(PQKBWorkID)10395016
035   $a(PQKB)11142716
035   $a(MiAaPQ)EBC589068
035   $a(Au-PeEL)EBL589068
035   $a(CaPaEBR)ebr10419055
035   $a(CaONFJC)MIL278289
035   $a(EXLCZ)992670000000047173
100   $a20100428d2010      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aBiotransformation and metabolite elucidation of xenobiotics$b[electronic resource] /$fedited by Ala F. Nassar
210   $aHoboken, N.J. $cJohn Wiley & Sons$d2010
215   $a1 online resource (342 p.)
300   $aDescription based upon print version of record.
311   $a0-470-50478-1 
320   $aIncludes bibliographical references and index.
327   $aBIOTRANSFORMATION AND METABOLITE ELUCIDATION OF XENOBIOTICS; CONTENTS; PREFACE; CONTRIBUTORS; CHAPTER 1: HUMAN BIOTRANSFORMATION; CHAPTER 2: ANALYTICAL TOOLS AND APPROACHES FOR METABOLITE IDENTIFICATION IN DRUG METABOLISM; CHAPTER 3: TOOLS OF CHOICE FOR ACCELERATING METABOLITE IDENTIFICATION: MASS SPECTROMETRY TECHNOLOGY DRIVES METABOLITE IDENTIFICATION STUDIES FORWARD; CHAPTER 4: IMPROVING DRUG DESIGN: CONSIDERATIONS FOR THE STRUCTURAL MODIFICATION PROCESS
327   $aCHAPTER 5: CASE STUDY: THE UNANTICIPATED LOSS OF N2 FROM NOVEL DNA ALKYLATING AGENT LAROMUSTINE BY COLLISION-INDUCED DISSOCIATION: NOVEL REARRANGEMENTSCHAPTER 6: CASE STUDY: IDENTIFICATION OF IN VITRO METABOLITE/DECOMPOSITION PRODUCTS OF THE NOVEL DNA ALKYLATING AGENT LAROMUSTINE; CHAPTER 7: STRATEGIES FOR THE DETECTION OF REACTIVE INTERMEDIATES IN DRUG DISCOVERY AND DEVELOPMENT; CHAPTER 8: SAFETY TESTING OF DRUG METABOLITES: MIST GUIDANCE IMPACT ON THE PRACTICE OF INDUSTRIAL DRUG METABOLISM; INDEX
330   $aThe goal of this book is to improve the readers' knowledge of metabolite elucidation in drug metabolism by exposing them to in depth coverage of the biotransformation of xenobiotics, strategies for identifying and characterizing metabolites, FDA guidelines, and case studies on how to improve the decision-making process in structural modification of drug candidates to reduce toxicity. The book consists of 8 chapters; it first provides an introduction on biotransformation of xenobiotics, and then presents modern approaches and strategies for dealing with metabolite characterization, using tool
606   $aXenobiotics$xMetabolism
606   $aMetabolites$vIdentification
606   $aBiotransformation (Metabolism)
615  0$aXenobiotics$xMetabolism.
615  0$aMetabolites
615  0$aBiotransformation (Metabolism)
676   $a615.9
701   $aNassar$b Ala F$01639399
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910806236703321
996   $aBiotransformation and metabolite elucidation of xenobiotics$93982347
997   $aUNINA